Goto K, et al. - In patients with advanced pancreatic or biliary tract cancer, researchers evaluated the prognostic value of the maximum chemiluminescence intensity (CI_max) for severe neutropenia (SN) during neoadjuvant chemo(radio)therapy (NAC[RT]). For this investigation, they assessed clinicopathological variables and blood test data before NAC(RT) in 64 subjects with advanced pancreatic or biliary tract cancer who received gemcitabine plus tegafur/gimeracil/oteracil as NAC(RT). They observed that a majority of the patients (81.8%) with a low CI_max before NAC(RT) had SN during NAC(RT). In patients with advanced pancreatic or biliary tract cancer, CI_max before NAC(RT) can predict SN during NAC(RT).